We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors

This study is currently recruiting participants.
Verified November 2011 by Cyclacel Pharmaceuticals, Inc.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00999401
First Posted: October 21, 2009
Last Update Posted: May 3, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Cyclacel Pharmaceuticals, Inc.
  Purpose
The primary objective of this study is to determine the maximum tolerated dose (MTD) or recommended phase II doses of sapacitabine and seliciclib administered sequentially or concomitantly. The secondary objectives are to evaluate antitumor activity of this sequential or concomitant treatment and to explore the pharmacodynamic effect of this treatment in skin and peripheral blood mononuclear cells.

Condition Intervention Phase
Advanced Solid Tumors Drug: sapacitabine and seliciclib Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors

Further study details as provided by Cyclacel Pharmaceuticals, Inc.:

Primary Outcome Measures:
  • maximum tolerated dose [ Time Frame: 1-3 months ]

Secondary Outcome Measures:
  • tumor response rate [ Time Frame: 1-3 months ]
  • pharmacodynamic effects in skin and peripheral mononuclear cells [ Time Frame: 1-3 months ]

Estimated Enrollment: 90
Study Start Date: April 2009
Estimated Study Completion Date: July 2018
Estimated Primary Completion Date: July 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: sapacitabine and seliciclib
Sequential or concomitant administration of sapacitabine and seliciclib
Drug: sapacitabine and seliciclib
sequential or concomitant administration of sapacitabine and seliciclib

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Incurable advanced solid tumors that are no longer responding to conventional therapy or for which no effective therapy exists; at the RD of Part 1, an extension cohort up to 20 patients with metastatic breast cancer who are known to be BRCA mutation carriers will be enrolled.
  • Age 18 years or older
  • ECOG 0-2
  • Life expectancy ≥ 3 months
  • Evaluable disease
  • Adequate bone marrow function
  • Adequate renal function
  • Adequate liver function
  • At least 3 weeks from prior systemic treatments including investigational anti-cancer therapy, radiation therapy; and have recovered from prior toxicities
  • Able to swallow capsules
  • At least 3 weeks from major surgery
  • Agree to practice effective contraception
  • Ability to understand and willingness to sign the informed consent form

Exclusion Criteria:

  • Previously untreated CNS metastases or progressive CNS metastases
  • Currently receiving radiotherapy, biological therapy, or any other investigational agents
  • Uncontrolled intercurrent illness including
  • Pregnant or lactating women
  • Known to be HIV-positive
  • A history of active hepatitis B and/or hepatitis C infection
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00999401


Locations
United States, Massachusetts
Dana Farber Cancer Institute Recruiting
Boston, Massachusetts, United States, 02115
Contact: Geoffrey Shapiro, M.D.    617-632-4942      
Contact: Tracy Bell, R.N.    617.632.3482      
Dana Farber Cancer Institute Recruiting
Boston, Massachusetts, United States, 02215
Contact: Sara Tolaney, M.D.    617-632-2335      
Contact: Leilani Anderson, RN    617-632-3129      
Sponsors and Collaborators
Cyclacel Pharmaceuticals, Inc.
Investigators
Principal Investigator: Geoffrey Shapiro, M.D. Dana-Farber Cancer Institute
Principal Investigator: Sara Tolaney, M.D. Dana-Farber Cancer Institute
  More Information

Additional Information:
Publications:
Shapiro GI, et al. Responses to sequential sapacitabine and seliciclib in patients with BRCA-deficient solid tumors. Cancer Res April 15, 2013 73; LB-202.

Responsible Party: Cyclacel Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT00999401     History of Changes
Other Study ID Numbers: CYC682-07
First Submitted: October 19, 2009
First Posted: October 21, 2009
Last Update Posted: May 3, 2016
Last Verified: November 2011

Additional relevant MeSH terms:
Roscovitine
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action